Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer
about
Human NKG2D-ligands: cell biology strategies to ensure immune recognitionNatural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomesA novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycansInteraction between natural killer cells and regulatory T cells: perspectives for immunotherapyNKG2D ligands as therapeutic targetsGlycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune RecognitionAn six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit sheddingPerturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions.Enhanced prevalence of plasmatic soluble MHC class I chain-related molecule in vascular pregnancy diseasesControl of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells.Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICALoss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma.Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.NKG2D-independent suppression of T cell proliferation by H60 and MICA.Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expressionThe regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding.MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.Opportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseRegulation of ligands for the NKG2D activating receptor.The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2DOncogenic stress sensed by the immune system: role of natural killer cell receptorsElevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patientsProstate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.NKG2D Receptor and Its Ligands in Host DefenseChimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1.Increased Soluble CD155 in the Serum of Cancer Patients.Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis.Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cellsMHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients.Regulation of ligands for the activating receptor NKG2D.IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
P2860
Q21131219-9C83ED53-8DCC-4F62-8A73-EE53348CC8B3Q24294847-369983C2-A4D5-4E32-85E0-44EBE49D0805Q24308236-9DF560FF-B474-4FEA-9404-AA196E2F7E02Q27008625-D0C8ECC4-C53E-4BF2-B818-BC8FEEAF912EQ27014888-C658B19A-97FE-47AF-9F3A-0195AAE6CEEDQ28076151-D522772F-2E11-4A31-A51F-372250C4C52CQ30489974-50E0B149-BCA0-45D4-8950-6A9B27CDB4EBQ30547087-B0AC9904-989B-45BA-841B-5B32052865FBQ33315601-86C1D0B4-4BA0-44C1-B725-83A581C80009Q33417775-0410176E-2403-47E9-A3BF-987D047CDB57Q33676231-EB8F3B60-258F-4994-9FED-92B01F2BF452Q33699687-5AA758CF-9D37-4500-BAFF-304EBF8CE8B8Q33825926-48EB6580-E4D6-490C-A2EA-CF3C38759C0AQ33898809-394A271D-E4BE-4EB8-B326-8E1B5AEE2EA7Q33909404-3D61C3E6-93EB-4802-BAEE-AC1F6FAEA9A2Q33920066-8BCBA8EA-3723-4F34-824E-948D456BDC75Q33999130-89DD7E4D-BF58-4C31-BC10-914A376AC2EFQ34068134-821E3B00-4E2F-491B-B087-8BF27A0DFCBCQ34217314-93328BFD-72F7-44C2-B574-F8A519AC7F8CQ34241771-33997D22-B5F8-478F-8805-BD9A94A6D37CQ34307792-65D67C4A-9051-4B6C-AE0A-359EF32E5EFDQ34321457-1855A452-7A96-4AEC-9C26-9BDBBEAAF4B8Q34467682-73E1B8B7-5C43-4D7E-8402-E5D660242DC8Q34473267-14D38AE9-6B88-46B6-A6BD-BB08667C8763Q34488774-C1787397-AD44-40BF-B309-B6AAB40C65C7Q35287627-1A5D7D3D-62B7-4B83-BCB4-16D00B059BF5Q35687826-F420387F-462D-400E-A373-675A7D6F33A5Q35848101-1343FE55-8FF6-43F2-85D5-64980BC149DDQ35969225-443E6476-D782-4904-BA8A-A97EA979D6ADQ35973096-C2CD2202-F6B4-4CC8-A599-37757DC906B7Q35980806-8F4107F5-4E7B-4372-99AC-972B8A66532AQ36106303-6A2E50A0-2416-4D49-BC60-575E18F4C0AAQ36110266-40113D1A-C66E-48CC-BED6-2840A6C56034Q36403637-3F78609C-BB33-462B-9A70-DBFA96CE9200Q36407095-F80D3576-AF43-4416-A015-7C36A38971DCQ36446189-5F6336F8-0B3D-4A74-B394-A497400FAD67Q36473179-A5D4974A-A63E-4D79-905D-B03425D656B9Q36572148-AFBA0210-CCBA-4F01-B143-D6467E2D9610Q36872056-B9A34BFD-84DB-45E8-A7DD-2DF5194241E5Q37040481-BE747D82-B193-4F1B-AA38-6D3D5A041D8B
P2860
Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prevalent expression of the im ...... by shedding in prostate cancer
@en
Prevalent expression of the im ...... y shedding in prostate cancer.
@nl
type
label
Prevalent expression of the im ...... by shedding in prostate cancer
@en
Prevalent expression of the im ...... y shedding in prostate cancer.
@nl
prefLabel
Prevalent expression of the im ...... by shedding in prostate cancer
@en
Prevalent expression of the im ...... y shedding in prostate cancer.
@nl
P2093
P2860
P356
P1476
Prevalent expression of the im ...... by shedding in prostate cancer
@en
P2093
David Cosman
Jennifer D Wu
Kathy Haugk
Lily M Higgins
Stephen R Plymate
P2860
P304
P356
10.1172/JCI22206
P407
P577
2004-08-01T00:00:00Z